New drug aims to unleash immune system on brain tumors

NCT ID NCT05916313

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times

Summary

This early-stage trial tests a new drug, BI 764532, in adults with a type of brain tumor (glioma) that has a specific marker called DLL3. The drug is designed to help the body's immune cells recognize and attack the tumor. The main goal is to find the highest safe dose, and participants who benefit may continue treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cantonal Hospital of Aarau

Aarau, CH-5001, Switzerland
Erasmus Medisch Centrum-ROTTERDAM-50697

Rotterdam, 3015 GD, Netherlands
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital del Mar

Barcelona, 08003, Spain
Klinikum der Universität München AÖR

München, 81377, Germany
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Salzburg Cancer Research Institute

Salzburg, 5020, Austria
University Hosp. Zurich

Zurich, 8901, Switzerland
University Hospital of Lausanne

Lausanne, 1101, Switzerland
University of California Irvine

Orange, California, 92868, United States
Universitätsklinikum Frankfurt

Frankfurt, 60596, Germany
Universitätsklinikum Tübingen

Tübingen, 72076, Germany

Conditions

Explore the condition pages connected to this study.

GLIOMA